TY  - BOOK
AU  - Ghosh, Raktim K
TI  - Defining the Role of Icosapent Ethyl in Clinical Practice. [Review]
SN  - 1175-3277
PY  - 2020///
KW  - *Eicosapentaenoic Acid/aa [Analogs & Derivatives]
KW  - *Hypertriglyceridemia/dt [Drug Therapy]
KW  - Drug Dosage Calculations
KW  - Eicosapentaenoic Acid/ad [Administration & Dosage]
KW  - Eicosapentaenoic Acid/ae [Adverse Effects]
KW  - Eicosapentaenoic Acid/tu [Therapeutic Use]
KW  - Humans
KW  - Randomized Controlled Trials as Topic
KW  - Risk Factors
KW  - MedStar Union Memorial Hospital
KW  - Journal Article
N1  - Available online from MWHC library: 2001 - 2009
N2  - The health benefit of fish oil, i.e. omega-3 fatty acids (omega-3 FA) has a long history of debate. While there are a number of medications to reduce serum triglyceride levels, none have shown unanimous cardiovascular (CV) benefits. The most recent Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) assessing the CV outcome of one highly purified prescription omega-3 FA has certainly rejuvenated the debate. While this trial has been regarded as one of the most important landmark trials in preventive cardiology, the tolerability issue in a very high dose (4 g/day, as administered in the trial) is still a matter of concern. This article summarizes the current status and future perspective of icosapent ethyl in clinical practice in light of REDUCE-IT
UR  - https://dx.doi.org/10.1007/s40256-020-00402-4
ER  -